{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T15:23:15Z","timestamp":1786116195667,"version":"build-2736575974"},"reference-count":27,"publisher":"Ovid Technologies (Wolters Kluwer Health)","license":[{"start":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T00:00:00Z","timestamp":1785888000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Achieving a pathological complete response (pCR) following neoadjuvant chemoimmunotherapy is closely associated with improved long-term outcomes in resectable non-small cell lung cancer (NSCLC). It remains unclear whether the addition of adjuvant immunotherapy will improve survival in patients with a pCR.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>In this real-world observational study, we enrolled 145 consecutive patients diagnosed with resectable stage IB\u2013IIIB NSCLC who achieved a pCR after three cycles of neoadjuvant chemoimmunotherapy and subsequently received surgery between July 2020 and December 2023. Patients were assigned to two groups based on whether they received adjuvant immunotherapy (i.e. neoadjuvant-adjuvant group and neoadjuvant-only group). Disease-free survival (DFS) and overall survival (OS) were compared between the two groups after inverse probability of treatment weighting (IPTW), and treatment-related adverse events (TRAEs) were summarized.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      A total of 145 patients were included in the final analysis, and 81 patients (55.9%) received adjuvant immunotherapy after achieving pCR. The median follow-up duration for the whole cohort was 39.0 months. Neither group reached a median DFS, and no DFS benefit favoring the neoadjuvant-adjuvant strategy over neoadjuvant-only strategy was observed (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.801) after applying IPTW. Similarly, no significant difference in OS was observed between the two groups (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.231). The addition of adjuvant immunotherapy did not lead to a significant increase in any-grade, grade \u22653, or severe TRAEs.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>This study found that the addition of adjuvant immunotherapy did not demonstrate a significant improvement in DFS or OS in NSCLC patients who achieved a pCR after preoperative chemoimmunotherapy. However, larger prospective studies are required to confirm these results due to the limited sample size and low number of events.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/cm9.0000000000004185","type":"journal-article","created":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T08:00:12Z","timestamp":1786003212000},"update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and safety of adjuvant immunotherapy after pathological complete response following neoadjuvant chemoimmunotherapy in patients with resectable NSCLC: A real-world observational study"],"prefix":"10.1097","author":[{"given":"Juan","family":"Jiang","sequence":"first","affiliation":[{"name":"Department of Respiratory Medicine, Xiangya Hospital, Central South University, Changsha, Hunan 410008, China"},{"name":"Xiangya Lung Cancer Center, Xiangya Hospital, Central South University, Changsha, Hunan 410008, China"},{"name":"Clinical Research Center for Respiratory Diseases in Hunan Province, Changsha, Hunan 410008, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziyu","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Xiangya Hospital, Central South University, Changsha, Hunan 410008, China"},{"name":"Xiangya Lung Cancer Center, Xiangya Hospital, Central South University, Changsha, Hunan 410008, China"},{"name":"Clinical Research Center for Respiratory Diseases in Hunan Province, Changsha, Hunan 410008, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Zeng","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, Xiangya Hospital, Central South University, Changsha, Hunan 410008, China"},{"name":"Hunan Engineering Research Center for Pulmonary Nodules Precise Diagnosis & Treatment, Changsha, Hunan 410008, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lemeng","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Thoracic Medicine Department I, Hunan Cancer Hospital\/The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, Hunan 410013, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingxiang","family":"Pu","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Lung Cancer and Gastrointestinal Unit, Hunan Cancer Hospital\/The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, Hunan 410013, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"An","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Xiangya Hospital, Central South University, Changsha, Hunan 410008, China"},{"name":"Xiangya Lung Cancer Center, Xiangya Hospital, Central South University, Changsha, Hunan 410008, China"},{"name":"Clinical Research Center for Respiratory Diseases in Hunan Province, Changsha, Hunan 410008, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanwu","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, Xiangya Hospital, Central South University, Changsha, Hunan 410008, China"},{"name":"Hunan Engineering Research Center for Pulmonary Nodules Precise Diagnosis & Treatment, Changsha, Hunan 410008, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pengbo","family":"Deng","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Xiangya Hospital, Central South University, Changsha, Hunan 410008, China"},{"name":"Xiangya Lung Cancer Center, Xiangya Hospital, Central South University, Changsha, Hunan 410008, China"},{"name":"Clinical Research Center for Respiratory Diseases in Hunan Province, Changsha, Hunan 410008, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruimin","family":"Chang","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, Xiangya Hospital, Central South University, Changsha, Hunan 410008, China"},{"name":"Hunan Engineering Research Center for Pulmonary Nodules Precise Diagnosis & Treatment, Changsha, Hunan 410008, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingxuan","family":"Xie","sequence":"additional","affiliation":[{"name":"Department of Geriatrics, Xiangya Hospital, Central South University, Changsha, Hunan 410008, China"},{"name":"National Clinical Research Center for Geriatric Disorders, Changsha, Hunan 410008, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoxiong","family":"Xiao","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, Xiangya Hospital, Central South University, Changsha, Hunan 410008, China"},{"name":"Hunan Engineering Research Center for Pulmonary Nodules Precise Diagnosis & Treatment, Changsha, Hunan 410008, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liming","family":"Cao","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Xiangya Hospital, Central South University, Changsha, Hunan 410008, China"},{"name":"Xiangya Lung Cancer Center, Xiangya Hospital, Central South University, Changsha, Hunan 410008, China"},{"name":"Clinical Research Center for Respiratory Diseases in Hunan Province, Changsha, Hunan 410008, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanda","family":"Cheng","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, Xiangya Hospital, Central South University, Changsha, Hunan 410008, China"},{"name":"Hunan Engineering Research Center for Pulmonary Nodules Precise Diagnosis & Treatment, Changsha, Hunan 410008, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huaping","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Xiangya Hospital, Central South University, Changsha, Hunan 410008, China"},{"name":"Xiangya Lung Cancer Center, Xiangya Hospital, Central South University, Changsha, Hunan 410008, China"},{"name":"Clinical Research Center for Respiratory Diseases in Hunan Province, Changsha, Hunan 410008, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengping","family":"Hu","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Xiangya Hospital, Central South University, Changsha, Hunan 410008, China"},{"name":"Xiangya Lung Cancer Center, Xiangya Hospital, Central South University, Changsha, Hunan 410008, China"},{"name":"Clinical Research Center for Respiratory Diseases in Hunan Province, Changsha, Hunan 410008, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Gao","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, Xiangya Hospital, Central South University, Changsha, Hunan 410008, China"},{"name":"Hunan Engineering Research Center for Pulmonary Nodules Precise Diagnosis & Treatment, Changsha, Hunan 410008, China"},{"name":"National Clinical Research Center for Geriatric Disorders, Changsha, Hunan 410008, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Xiangya Hospital, Central South University, Changsha, Hunan 410008, China"},{"name":"Xiangya Lung Cancer Center, Xiangya Hospital, Central South University, Changsha, Hunan 410008, China"},{"name":"Clinical Research Center for Respiratory Diseases in Hunan Province, Changsha, Hunan 410008, China"},{"name":"National Clinical Research Center for Geriatric Disorders, Changsha, Hunan 410008, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,8,5]]},"reference":[{"key":"R1-20260806","doi-asserted-by":"crossref","first-page":"3425","DOI":"10.1097\/CM9.0000000000003871","article-title":"Cancer burden and the contributions of risk factors in China: A systematic analysis for the Global Burden of Disease Study 2021","volume":"138","author":"Wu","year":"2025","journal-title":"Chin Med J"},{"key":"R2-20260806","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1016\/S1470-2045(20)30453-8","article-title":"Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): An open-label, multicentre, single-arm, phase 2 trial","volume":"21","author":"Provencio","year":"2020","journal-title":"Lancet Oncol"},{"key":"R3-20260806","first-page":"138","article-title":"Lung cancer-major changes in the American Joint Committee on Cancer eighth edition cancer staging manual","volume":"67","author":"Rami-Porta","year":"2017","journal-title":"CA Cancer J Clin"},{"key":"R4-20260806","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1056\/NEJMoa2202170","article-title":"Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer","volume":"386","author":"Forde","year":"2022","journal-title":"N Engl J Med"},{"key":"R5-20260806","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1001\/jama.2023.24735","article-title":"Perioperative Toripalimab Plus Chemotherapy for Patients With Resectable Non-Small Cell Lung Cancer: The Neotorch Randomized Clinical Trial","volume":"331","author":"Lu","year":"2024","journal-title":"JAMA"},{"key":"R6-20260806","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1001\/jamaoncol.2024.0057","article-title":"Neoadjuvant Chemoimmunotherapy for NSCLC: A Systematic Review and Meta-Analysis","volume":"10","author":"Sorin","year":"2024","journal-title":"JAMA Oncol"},{"key":"R7-20260806","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1056\/NEJMoa2215530","article-title":"Perioperative Nivolumab and Chemotherapy in Stage III Non-Small-Cell Lung Cancer","volume":"389","author":"Provencio","year":"2023","journal-title":"N Engl J Med"},{"key":"R9-20260806","doi-asserted-by":"crossref","DOI":"10.1093\/jncics\/pkae021","article-title":"Pathological response in resectable non-small cell lung cancer: a systematic literature review and meta-analysis","volume":"8","author":"Waser","year":"2024","journal-title":"JNCI Cancer Spectr"},{"key":"R10-20260806","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1016\/j.jtho.2024.03.010","article-title":"Evaluation of Major Pathologic Response and Pathologic Complete Response as Surrogate End Points for Survival in Randomized Controlled Trials of Neoadjuvant Immune Checkpoint Blockade in Resectable in NSCLC","volume":"19","author":"Hines","year":"2024","journal-title":"J Thorac Oncol"},{"key":"R11-20260806","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1038\/s41591-023-02660-6","article-title":"Association between pathologic response and survival after neoadjuvant therapy in lung cancer","volume":"30","author":"Deutsch","year":"2024","journal-title":"Nat Med"},{"key":"R12-20260806","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1016\/S0140-6736(21)02098-5","article-title":"Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower010): A randomised, multicentre, open-label, phase 3 trial","volume":"398","author":"Felip","year":"2021","journal-title":"Lancet"},{"key":"R13-20260806","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1016\/S1470-2045(22)00518-6","article-title":"Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB-IIIA non-small-cell lung cancer (PEARLS\/KEYNOTE-091): An interim analysis of a randomised, triple-blind, phase 3 trial","volume":"23","author":"O\u2019Brien","year":"2022","journal-title":"Lancet Oncol"},{"key":"R14-20260806","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.jtho.2024.11.004","article-title":"Adjuvant Immunotherapy Should Be Used in Patients With Non-Small Cell Carcinoma With a Pathologic Complete Response to Neoadjuvant Immunotherapy","volume":"20","author":"Uprety","year":"2025","journal-title":"J Thorac Oncol"},{"key":"R15-20260806","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.jtho.2024.10.010","article-title":"Adjuvant Immunotherapy Should Not be Used in Patients With a Pathologic Complete Response to Neoadjuvant Chemoimmunotherapy","volume":"20","author":"Phillips","year":"2025","journal-title":"J Thorac Oncol"},{"key":"R16-20260806","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/j.jtho.2020.01.005","article-title":"IASLC Multidisciplinary Recommendations for Pathologic Assessment of Lung Cancer Resection Specimens After Neoadjuvant Therapy","volume":"15","author":"Travis","year":"2020","journal-title":"J Thorac Oncol"},{"key":"R17-20260806","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1038\/nature24473","article-title":"A neoantigen fitness model predicts tumour response to checkpoint blockade immunotherapy","volume":"551","author":"\u0141uksza","year":"2017","journal-title":"Nature"},{"key":"R18-20260806","doi-asserted-by":"crossref","first-page":"1976","DOI":"10.1056\/NEJMoa1716078","article-title":"Neoadjuvant PD-1 Blockade in Resectable Lung Cancer","volume":"378","author":"Forde","year":"2018","journal-title":"N Engl J Med"},{"key":"R19-20260806","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1056\/NEJMoa2304875","article-title":"Perioperative Durvalumab for Resectable Non-Small-Cell Lung Cancer","volume":"389","author":"Heymach","year":"2023","journal-title":"N Engl J Med"},{"key":"R20-20260806","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1016\/S0140-6736(24)01756-2","article-title":"Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab compared with neoadjuvant chemotherapy alone in patients with early-stage non-small-cell lung cancer (KEYNOTE-671): A randomised, double-blind, placebo-controlled, phase 3 trial","volume":"404","author":"Spicer","year":"2024","journal-title":"Lancet"},{"key":"R21-20260806","doi-asserted-by":"crossref","first-page":"e241285","DOI":"10.1001\/jamanetworkopen.2024.1285","article-title":"Neoadjuvant-Adjuvant vs Neoadjuvant-Only PD-1 and PD-L1 Inhibitors for Patients With Resectable NSCLC: An Indirect Meta-Analysis","volume":"7","author":"Zhou","year":"2024","journal-title":"JAMA Netw Open"},{"key":"R22-20260806","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.jtho.2024.09.1443","article-title":"Improved Event-Free Survival After Complete or Major Pathologic Response in Patients With Resectable NSCLC Treated With Neoadjuvant Chemoimmunotherapy Regardless of Adjuvant Treatment: A Systematic Review and Individual Patient Data Meta-Analysis","volume":"20","author":"Marinelli","year":"2025","journal-title":"J Thorac Oncol"},{"key":"R23-20260806","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1056\/NEJMoa2302983","article-title":"Perioperative Pembrolizumab for Early-Stage Non-Small-Cell Lung Cancer","volume":"389","author":"Wakelee","year":"2023","journal-title":"N Engl J Med"},{"key":"R24-20260806","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1056\/NEJMoa2311926","article-title":"Perioperative Nivolumab in Resectable Lung Cancer","volume":"390","author":"Cascone","year":"2024","journal-title":"N Engl J Med"},{"key":"R25-20260806","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1038\/s41571-022-00664-8","article-title":"When can we be confident of surgical cure with ctDNA","volume":"19","author":"Frankell","year":"2022","journal-title":"Nat Rev Clin Oncol"},{"issue":"17_suppl","key":"R26-20260806","doi-asserted-by":"crossref","first-page":"LBA8010","DOI":"10.1200\/JCO.2025.43.17_suppl.LBA8010","article-title":"Perioperative nivolumab vs placebo in patients with resectable NSCLC: Updated survival and biomarker analyses from CheckMate 77T","volume":"43","author":"Cascone","year":"2025","journal-title":"J Clin Oncol"},{"key":"R27-20260806","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1016\/j.ccell.2023.07.011","article-title":"Neoadjuvant immune checkpoint blockade: A window of opportunity to advance cancer immunotherapy","volume":"41","author":"Topalian","year":"2023","journal-title":"Cancer Cell"},{"key":"R28-20260806","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/S1470-2045(23)00524-7","article-title":"Treatment-related adverse events, including fatal toxicities, in patients with solid tumours receiving neoadjuvant and adjuvant immune checkpoint blockade: A systematic review and meta-analysis of randomised controlled trials","volume":"25","author":"Fujiwara","year":"2024","journal-title":"Lancet Oncol"}],"container-title":["Chinese Medical Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/CM9.0000000000004185","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T08:00:15Z","timestamp":1786003215000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/CM9.0000000000004185"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,5]]},"references-count":27,"URL":"https:\/\/doi.org\/10.1097\/cm9.0000000000004185","relation":{},"ISSN":["0366-6999","2542-5641"],"issn-type":[{"value":"0366-6999","type":"print"},{"value":"2542-5641","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,5]]},"assertion":[{"value":"2025-09-30","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}}]}}